drugset / Trial / NCT00127647

An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)

NCT00127647

Phase 3 Completed 1375 enrolled Organon and Co
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to evaluate the efficacy and safety of an investigational drug in adult patients with allergic rhinitis.

Timeline

Start
2004-11
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 5 mg Oral
Subject Montelukast Other / unclassified 10 mg Oral
Comparator Pranlukast Small molecule 225 mg Oral